Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.

Daneshmanesh AH, Hojjat-Farsangi M, Ghaderi A, Moshfegh A, Hansson L, Schultz J, Vågberg J, Byström S, Olsson E, Olin T, Österborg A, Mellstedt H.

PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018.

2.

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.

Hojjat-Farsangi M, Daneshmanesh AH, Khan AS, Shetye J, Mozaffari F, Kharaziha P, Rathje LS, Kokhaei P, Hansson L, Vågberg J, Byström S, Olsson E, Löfberg C, Norström C, Schultz J, Norin M, Olin T, Österborg A, Mellstedt H, Moshfegh A.

Leukemia. 2018 Mar 27. doi: 10.1038/s41375-018-0113-1. [Epub ahead of print] No abstract available.

PMID:
29725030
3.

Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.

Palma M, Hansson L, Mulder TA, Adamson L, Näsman-Glaser B, Eriksson I, Heimersson K, Ryblom H, Mozaffari F, Svensson A, Gentilcore G, Österborg A, Mellstedt H.

Eur J Haematol. 2018 Mar 23. doi: 10.1111/ejh.13065. [Epub ahead of print]

PMID:
29569742
4.

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.

Kokhaei P, Hojjat-Farsangi M, Mozaffari F, Moshfegh A, Pak F, Rashidy-Pour A, Palma M, Hansson L, Österborg A, Mellstedt H.

PLoS One. 2018 Feb 12;13(2):e0192839. doi: 10.1371/journal.pone.0192839. eCollection 2018.

5.

European Perspective on Biosimilars.

Mellstedt H.

J Oncol Pract. 2017 Sep;13(9_suppl):15s-16s. doi: 10.1200/JOP.2017.025569. No abstract available.

PMID:
28898594
6.

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.

Winqvist M, Palma M, Heimersson K, Mellstedt H, Österborg A, Lundin J.

Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14836. [Epub ahead of print] No abstract available.

PMID:
28677818
7.

Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.

Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, Heiland T, Halatsch ME.

Tumour Biol. 2017 May;39(5):1010428317699797. doi: 10.1177/1010428317699797. Review.

PMID:
28459367
8.

Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].

Garcia C, Rosén A, Kimby E, Aguilar-Santelises M, Jondal M, Björkholm M, Holm G, Mellstedt H.

Leuk Res. 2017 Jun;57:127. doi: 10.1016/j.leukres.2017.01.029. Epub 2017 Mar 15. No abstract available.

PMID:
28314441
9.

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

Ullenhag GJ, Mozaffari F, Broberg M, Mellstedt H, Liljefors M.

PLoS One. 2017 Jan 18;12(1):e0169736. doi: 10.1371/journal.pone.0169736. eCollection 2017.

10.

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Palma M, Gentilcore G, Heimersson K, Mozaffari F, Näsman-Glaser B, Young E, Rosenquist R, Hansson L, Österborg A, Mellstedt H.

Haematologica. 2017 Mar;102(3):562-572. doi: 10.3324/haematol.2016.151100. Epub 2016 Dec 7.

11.

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J.

Cancer Immunol Immunother. 2017 Jan;66(1):91-102. doi: 10.1007/s00262-016-1922-6. Epub 2016 Nov 4.

12.

Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.

Khan AS, Hojjat-Farsangi M, Daneshmanesh AH, Hansson L, Kokhaei P, Österborg A, Mellstedt H, Moshfegh A.

Tumour Biol. 2016 Sep;37(9):11947-11957. Epub 2016 Apr 16.

PMID:
27086035
13.

Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Högfeldt T, Jaing C, Loughlin KM, Thissen J, Gardner S, Bahnassy AA, Gharizadeh B, Lundahl J, Österborg A, Porwit A, Zekri AN, Khaled HM, Mellstedt H, Moshfegh A.

Oncol Lett. 2016 Oct;12(4):2782-2788. Epub 2016 Aug 16.

14.

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.

Hojjat-Farsangi M, Jeddi-Tehrani M, Daneshmanesh AH, Mozaffari F, Moshfegh A, Hansson L, Razavi SM, Sharifian RA, Rabbani H, Österborg A, Mellstedt H, Shokri F.

PLoS One. 2015 Nov 12;10(11):e0142310. doi: 10.1371/journal.pone.0142310. eCollection 2015.

15.

Biosimilars - terms of use.

Declerck P, Mellstedt H, Danese S.

Curr Med Res Opin. 2015 Dec;31(12):2325-30. doi: 10.1185/03007995.2015.1098601. Epub 2015 Oct 27. Review.

PMID:
26397731
16.

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

Kokhaei P, Jadidi-Niaragh F, Sotoodeh Jahromi A, Osterborg A, Mellstedt H, Hojjat-Farsangi M.

J Drug Target. 2016;24(5):373-85. doi: 10.3109/1061186X.2015.1086357. Epub 2015 Sep 11. Review.

PMID:
26362595
17.

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.

Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, Österborg A, Lundqvist A.

Eur J Immunol. 2015 Jun;45(6):1783-93. doi: 10.1002/eji.201444885. Epub 2015 Apr 17.

18.

Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Rossmann E, Österborg A, Löfvenberg E, Choudhury A, Forssmann U, von Heydebreck A, Schröder A, Mellstedt H.

Hum Vaccin Immunother. 2014;10(11):3394-408. doi: 10.4161/hv.29918.

19.

Awareness and understanding of cancer immunotherapy in Europe.

Mellstedt H, Gaudernack G, Gerritsen WR, Huber C, Melero I, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C.

Hum Vaccin Immunother. 2014;10(7):1828-35. doi: 10.4161/hv.28943.

20.

The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.

Daneshmanesh AH, Hojjat-Farsangi M, Moshfegh A, Khan AS, Mikaelsson E, Österborg A, Mellstedt H.

Br J Haematol. 2015 May;169(3):455-8. doi: 10.1111/bjh.13228. Epub 2014 Nov 19. No abstract available.

PMID:
25407287
21.

The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.

Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H.

Semin Cancer Biol. 2014 Dec;29:21-31. doi: 10.1016/j.semcancer.2014.07.005. Epub 2014 Jul 25. Review.

PMID:
25068995
22.

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J.

J Gynecol Oncol. 2014 Jul;25(3):221-8. doi: 10.3802/jgo.2014.25.3.221. Epub 2014 Jul 3.

23.

Therapeutic vaccines for cancer: an overview of clinical trials.

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H.

Nat Rev Clin Oncol. 2014 Sep;11(9):509-24. doi: 10.1038/nrclinonc.2014.111. Epub 2014 Jul 8. Review.

PMID:
25001465
24.

[Cheaper with biosimilars, but safety comes first].

Mellstedt H.

Lakartidningen. 2014 May 27-Jun 10;111(22-23):1011. Swedish. No abstract available.

25.

Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.

Staff C, Mozaffari F, Frödin JE, Mellstedt H, Liljefors M.

Int J Oncol. 2014 Sep;45(3):1293-303. doi: 10.3892/ijo.2014.2496. Epub 2014 Jun 11.

PMID:
24919654
26.

Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells.

Mikaelsson E, Osterborg A, Tahmasebi Fard Z, Mahmoudi A, Mahmoudian J, Jeddi-Tehrani M, Akhondi M, Shokri F, Bishop PN, Rabbani H, Mellstedt H.

Exp Hematol Oncol. 2013 Aug 28;2(1):23. doi: 10.1186/2162-3619-2-23.

27.

Clinical considerations for biosimilar antibodies.

Mellstedt H.

EJC Suppl. 2013 Dec;11(3):1-11. doi: 10.1016/S1359-6349(13)70001-6.

28.

The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.

Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, Moshfegh A, Sandin A, Mansouri L, Palma M, Lundin J, Österborg A, Mellstedt H.

PLoS One. 2013 Oct 24;8(10):e78339. doi: 10.1371/journal.pone.0078339. eCollection 2013.

29.

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

Mellstedt H.

Ann Oncol. 2013 Sep;24 Suppl 5:v23-8. doi: 10.1093/annonc/mdt325.

PMID:
23975701
30.

Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.

Högfeldt T, Johnsson P, Grandér D, Bahnassy AA, Porwit A, Eid S, Österborg A, Zekri AR, Lundahl J, Khaled MH, Mellstedt H, Moshfegh A.

Leuk Lymphoma. 2014 May;55(5):1158-65. doi: 10.3109/10428194.2013.824077. Epub 2013 Aug 31.

PMID:
23841503
31.

A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.

Mikaelsson E, Österborg A, Jeddi-Tehrani M, Kokhaei P, Ostadkarampour M, Hadavi R, Gholamin M, Akhondi M, Shokri F, Rabbani H, Mellstedt H.

PLoS One. 2013 Jun 24;8(6):e67601. doi: 10.1371/journal.pone.0067601. Print 2013.

32.

Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.

Pietzner K, Woopen H, Richter R, Joens T, Braicu EI, Dimitrova D, Mellstedt H, Darb-Esfahani S, Denkert C, Lindhofer H, Fotopoulou C, Sehouli J.

Int J Gynecol Cancer. 2013 Jun;23(5):797-802. doi: 10.1097/IGC.0b013e3182929056.

PMID:
23694980
33.

Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.

Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi-Tehrani M, Rabbani H, Mellstedt H.

PLoS One. 2013 Apr 8;8(4):e61167. doi: 10.1371/journal.pone.0061167. Print 2013.

34.

Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia.

Palma M, Parker A, Hojjat-Farsangi M, Forster J, Kokhaei P, Hansson L, Osterborg A, Mellstedt H.

Exp Hematol. 2013 Jul;41(7):615-26. doi: 10.1016/j.exphem.2013.03.008. Epub 2013 Mar 30.

PMID:
23548418
35.

Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures.

Högfeldt T, Bahnassy AA, Kwiecinska A, Osterborg A, Tamm KP, Porwit A, Zekri AR, Lundahl J, Khaled HM, Mellstedt H, Moshfegh A.

Leuk Lymphoma. 2013 May;54(5):996-1003. doi: 10.3109/10428194.2012.738365. Epub 2012 Nov 8.

PMID:
23046110
36.

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.

Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grandér D, Lehmann S, Norin S, Shokri F, Rabbani H, Mellstedt H, Österborg A.

Leuk Lymphoma. 2013 Apr;54(4):843-50. doi: 10.3109/10428194.2012.731599. Epub 2012 Oct 9.

PMID:
22988987
37.

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia.

Karlsson C, Dahl H, Lundin J, Rossmann E, Brytting M, Mellstedt H, Linde A, Osterborg A.

Blood Cancer J. 2011 Jun;1(6):e22. doi: 10.1038/bcj.2011.20. Epub 2011 Jun 10. No abstract available.

38.

T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.

Kiaii S, Kokhaei P, Mozaffari F, Rossmann E, Pak F, Moshfegh A, Palma M, Hansson L, Mashayekhi K, Hojjat-Farsangi M, Österborg A, Choudhury A, Mellstedt H.

Cancer Immunol Immunother. 2013 Jan;62(1):51-63. doi: 10.1007/s00262-012-1300-y. Epub 2012 Jun 27.

PMID:
22736254
39.

Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.

Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frödin JE, Wahrén B, Mellstedt H, Ullenhag GJ.

J Clin Immunol. 2012 Aug;32(4):855-65. doi: 10.1007/s10875-012-9662-7. Epub 2012 Mar 2.

PMID:
22382876
40.

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.

Daneshmanesh AH, Hojjat-Farsangi M, Khan AS, Jeddi-Tehrani M, Akhondi MM, Bayat AA, Ghods R, Mahmoudi AR, Hadavi R, Österborg A, Shokri F, Rabbani H, Mellstedt H.

Leukemia. 2012 Jun;26(6):1348-55. doi: 10.1038/leu.2011.362. Epub 2012 Jan 6.

PMID:
22289919
41.

First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.

Choudhury A, Höglund P, Kiessling R, Kärre K, Lundqvist A, Malmberg K, Mellstedt H, Scheynius A, Winqvist O, Osterborg A.

Cancer Immunol Immunother. 2012 Apr;61(4):587-91. doi: 10.1007/s00262-011-1177-1. Epub 2012 Jan 15. No abstract available.

PMID:
22246566
42.

[Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].

Mellstedt H, Gimsing P, Waage A.

Lakartidningen. 2011 Oct 19-25;108(42):2090-4. Review. Swedish. No abstract available.

PMID:
22165535
43.

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.

Palma M, Hansson L, Choudhury A, Näsman-Glaser B, Eriksson I, Adamson L, Rossmann E, Widén K, Horváth R, Kokhaei P, Vertuani S, Mellstedt H, Osterborg A.

Cancer Immunol Immunother. 2012 Jun;61(6):865-79. doi: 10.1007/s00262-011-1149-5. Epub 2011 Nov 16.

PMID:
22086161
44.

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.

Patriarca C, Macchi RM, Marschner AK, Mellstedt H.

Cancer Treat Rev. 2012 Feb;38(1):68-75. doi: 10.1016/j.ctrv.2011.04.002. Epub 2011 May 14. Review.

PMID:
21576002
45.

Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.

Mellstedt H, Vansteenkiste J, Thatcher N.

Lung Cancer. 2011 Jul;73(1):11-7. doi: 10.1016/j.lungcan.2011.02.023. Epub 2011 Apr 6. Review.

PMID:
21474197
46.

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, Chum P, Yan XJ, Allen SL, Kolitz JE, Baskar S, Rader C, Mellstedt H, Rabbani H, Lee A, Gregersen PK, Rai KR, Chiorazzi N.

Blood. 2011 May 19;117(20):5463-72. doi: 10.1182/blood-2010-12-324210. Epub 2011 Mar 8.

47.

Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer.

Jacobson TA, Lundahl J, Mellstedt H, Moshfegh A.

Int J Oncol. 2011 Apr;38(4):1075-81. doi: 10.3892/ijo.2011.936. Epub 2011 Feb 8.

PMID:
21305253
48.

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.

Wang B, Kokhaei P, Mellstedt H, Liljefors M.

Int J Oncol. 2010 Dec;37(6):1599-606.

PMID:
21042730
49.

Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.

Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, Kokhaei P, Osterborg A, Mellstedt H.

Br J Haematol. 2010 Nov;151(4):327-35. doi: 10.1111/j.1365-2141.2010.08362.x. Epub 2010 Aug 31.

PMID:
20813009
50.

Implications of the development of biosimilars for cancer treatment.

Mellstedt H.

Future Oncol. 2010 Jul;6(7):1065-7. doi: 10.2217/fon.10.72. No abstract available.

Supplemental Content

Loading ...
Support Center